Sibeprenlimab in IgA Nephropathy – Phase 3 Trial Results
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- These findings primarily affect adults with obesity *and* pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated important weight loss, the cardiovascular safety signal is prompting a reassessment of its use in this specific patient population.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. Importantly, the weight loss achieved with semaglutide - an average of approximately 15% of initial body weight – did *not* appear to offset this cardiovascular risk. The findings were consistent across various subgroups, even though some signals were more pronounced in those with prior heart failure.
| Event | Semaglutide Group (%) | Placebo Group (%) |
|---|---|---|
| Cardiovascular Death | 1.5% | 1.2% |
| Non-Fatal Stroke | 1.7% | 1.3% |
| Non-Fatal Heart Attack | 3.4% | 2.4% |
| MACE (Combined) | 6.5% | 4.9% |
Who is Affected? Understanding Patient risk
These findings primarily affect adults with obesity *and* pre-existing cardiovascular disease. This includes individuals with a history of heart attack, stroke, peripheral artery disease, or established heart failure. The trial did *not* include patients with type 2 diabetes, so the results cannot be directly extrapolated to that population. However, given that semaglutide is frequently used off-label for weight loss in individuals without diabetes, these results raise important questions about broader safety considerations.
It’s crucial to differentiate between this population and those using semaglutide for diabetes management,where previous trials (like LEVOSTAR) have shown cardiovascular *benefit*. The SELECT trial focused specifically on a higher-risk cohort.
Why Does This Matter? The Complex Relationship Between Weight Loss and Cardiovascular Health
The unexpected finding of increased cardiovascular risk despite significant weight loss highlights the complex interplay between obesity, weight loss interventions, and cardiovascular health. Rapid weight loss, particularly with medications, can sometimes induce metabolic shifts and electrolyte imbalances that may temporarily increase cardiovascular strain. Moreover, the underlying mechanisms driving cardiovascular disease in this population are frequently enough multifactorial and may not be solely addressed by weight reduction.